interaction records 54 assistance programs 55 0 personal data stored
OmniRx › Tools › Generic competition check › Crizotinib

Generic competition · all medicines · read 12 November 2026

Is there a generic of Crizotinib, and who makes it?

Crizotinib appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming. This is the Orange Book's listing, not a forecast.

Compiled and checked by Vincent Wesley Couey (ORCID 0009-0005-6869-308X) from the Orange Book data files, downloaded 12 November 2026.

Not medical advice. This page reports what the FDA's Orange Book lists, not what a pharmacy has in stock, what anything costs, or whether a generic is right for you. Ask your pharmacist or prescriber about your own medicine.
Crizotinib2 dosage-form groups in the Orange Book
0generic makers listed
  1. Crizotinib appears in 2 dosage-form groups in the FDA Orange Book as of 12 November 2026, with no generic maker listed as marketed.
  2. 2 groups have a brand listed as marketed and no generic listed as marketed. The data does not state why, and it does not state that one is coming.
  3. Patents and exclusivities are shown as listed by the application holder; the Orange Book does not rule on them, and a listed patent is not a statement that a generic is blocked. This says nothing about price, supply or quality.

Capsule, Pellets, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Xalkori. No generic is listed as marketed.

20202025203001brand 2023data datePatent 7825137 listed to expire 12 May 2027Patent 7858643 listed to expire 8 October 2029Patent 8217057 listed to expire 6 November 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 12 May 2027Patent 7825137
  • 8 October 2029Patent 7858643 drug substance
  • 6 November 2029Patent 8217057 drug substance

Capsule, Oral

Brand listed, no generic listed as marketed

Brand listed as marketed: Xalkori. No generic is listed as marketed.

2010201520202025203001brand 2011data datePatent 7825137 listed to expire 12 May 2027Patent 7858643 listed to expire 8 October 2029Patent 8217057 listed to expire 6 November 2029Exclusivity ODE-328 to 14 January 2028Exclusivity ODE-407 to 14 July 2029
generic makers listed as marketed, by first approvallisted patent expiryexclusivity end

Patents and exclusivities still listed

  • 14 January 2028Exclusivity ODE-328 Xalkori
  • 14 July 2029Exclusivity ODE-407 Xalkori
  • 12 May 2027Patent 7825137
  • 8 October 2029Patent 7858643 drug substance
  • 6 November 2029Patent 8217057 drug substance

US Food and Drug Administration, Orange Book data files, downloaded 12 November 2026. A listed patent is not a ruling that a generic is blocked, and no figure here says anything about price, supply or quality. Check the Orange Book.

Where can you go from this result?

Open it in the check to search another medicine, or see every brand with no generic listed. The FDA explains generic approval in how generic drugs are approved and the FDA generic drug facts, and the Orange Book itself is the FDA Orange Book. To check what is available now, ask your pharmacist, and see the FDA drug shortages page.